Nitric Oxide‐Induced Changes in Endothelial Expression of Phosphodiesterases 2, 3, and 5

(Headache 2010;50:431‐441)

[1]  L. Edvinsson,et al.  The Blood-Brain Barrier in Migraine Treatment , 2008, Cephalalgia : an international journal of headache.

[2]  J. Olesen.  The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. , 2008, Pharmacology & therapeutics.

[3]  K. Black,et al.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model , 2008, Brain Research.

[4]  J. Garthwaite.  Concepts of neural nitric oxide-mediated transmission , 2008, The European journal of neuroscience.

[5]  J. Mostert,et al.  Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders , 2008, Journal of the Neurological Sciences.

[6]  U. Landmesser,et al.  Endothelial Dysfunction as an Early Sign of Atherosclerosis , 2007, Herz Kardiovaskuläre Erkrankungen.

[7]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[8]  J. Olesen,et al.  The Headache-Inducing Effect of Cilostazol in Human Volunteers , 2006, Cephalalgia : an international journal of headache.

[9]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[10]  J. Olesen,et al.  Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system , 2006, Neuroscience Letters.

[11]  Yongge Liu,et al.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. , 2006, Cardiovascular drug reviews.

[12]  K. Bloch,et al.  Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[13]  J. Olesen,et al.  Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. , 2005, European journal of pharmacology.

[14]  B. Zhu,et al.  Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[15]  D. Maurice.  Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. , 2005, Frontiers in bioscience : a journal and virtual library.

[16]  M. Chopp,et al.  Functional Recovery in Aged and Young Rats After Embolic Stroke: Treatment With a Phosphodiesterase Type 5 Inhibitor , 2005, Stroke.

[17]  A. Straube,et al.  Calcineurin Inhibitor‐Induced Headache: Clinical Characteristics and Possible Mechanisms , 2005, Headache.

[18]  S. Vincent,et al.  Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood–brain barrier , 2004, Experimental Neurology.

[19]  J. Olesen,et al.  The Phosphodiesterase 3 Inhibitor Cilostazol Dilates Large Cerebral Arteries in Humans without Affecting Regional Cerebral Blood Flow , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  H. Kaube,et al.  Glyceryl trinitrate triggers premonitory symptoms in migraineurs , 2004, Pain.

[21]  C. Harris,et al.  Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Cowland,et al.  End‐stage differentiation of neutrophil granulocytes in vivo is accompanied by up‐regulation of p27kip1 and down‐regulation of CDK2, CDK4, and CDK6 , 2004, Journal of leukocyte biology.

[23]  Hisham S. Elbatarny,et al.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. , 2003, Molecular pharmacology.

[24]  H. Brunner-La Rocca,et al.  Interaction of Sildenafil With cAMP-Mediated Vasodilation In Vivo , 2002, Hypertension.

[25]  W. Hol,et al.  GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. , 2002, Molecular interventions.

[26]  J. Olesen,et al.  The Phosphodiesterase 5 Inhibitor Sildenafil Has No Effect on Cerebral Blood Flow or Blood Velocity, but Nevertheless Induces Headache in Healthy Subjects , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  T. Ashikaga,et al.  Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). , 2002, Biochemical pharmacology.

[28]  J. Olesen,et al.  Cgrp May Play A Causative Role in Migraine , 2002, Cephalalgia : an international journal of headache.

[29]  M. Moskowitz,et al.  Delayed inflammation in rat meninges: implications for migraine pathophysiology. , 2001, Brain : a journal of neurology.

[30]  J. Beavo,et al.  Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance , 2001, Circulation.

[31]  H. Iversen.  Human Migraine Models , 2001, Cephalalgia : an international journal of headache.

[32]  F. Murad,et al.  NO, nitrotyrosine, and cyclic GMP in signal transduction. , 2001, Medical Science Monitor.

[33]  K. Kikuta,et al.  Milrinone for the Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage: Report of Seven Cases , 2001, Neurosurgery.

[34]  C. Sobey,et al.  Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage. , 1999, American journal of physiology. Heart and circulatory physiology.

[35]  L. Thomsen.  Investigations Into the Role of Nitric Oxide and the Large Intracranial Arteries in Migraine Headache , 1997, Cephalalgia : an international journal of headache.

[36]  J. Olesen,et al.  Nitric oxide synthase inhibition in migraine , 1997, The Lancet.

[37]  R. Willette,et al.  Identification, Characterization, and Functional Role of Phosphodiesterase Type IV in Cerebral Vessels: Effects of Selective Phosphodiesterase Inhibitors , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  S. Moncada,et al.  Molecular mechanisms and therapeutic strategies related to nitric oxide , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  M. Chopp,et al.  Nitric Oxide Measured by a Porphyrinic Micro Sensor in Rat Brain after Transient Middle Cerebral Artery Occlusion , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  R. Haslam,et al.  Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. , 1990, Molecular pharmacology.

[41]  S. Moncada,et al.  Nitric oxide and the vascular endothelium. , 2006, Handbook of experimental pharmacology.

[42]  J. Olesen,et al.  Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. , 2003, Brain : a journal of neurology.

[43]  M. Stins,et al.  Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. , 2001, Microbial pathogenesis.

[44]  K. M. Davies,et al.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.